Efficacy and safety of robotic Cyberknife radiotherapy in uveal melanoma: A systematic review and meta-analysis
Objectives:
This systematic review is aimed to evaluate the efficacy and safety of robotic Cyberknife radiotherapy (CKRT) in the treatment of uveal melanoma (UM).
Methods:
Clinical studies published in English that assessed the efficacy and safety of robotic CKRT in UM were systematically searched in PubMed, Web of Science, Cochrane and Embase from inception to July 2023. Studies reporting extraocular tumours or other radiosurgery approaches were excluded. Outcomes measured were tumour size, reflectivity, local tumour control rate, eye retention rate, survival rate, complication rate, recurrence rate, and metastasis rate.
Results:
Ten eligible articles involving 2370 patients with 2372 UMs were included in evidence synthesis. Meta-analysis showed 811 of 912 patients (0.89, 95% Cl: 0.86, 0.92) maintained local control for three years, and 1448 of 1724 patients (0.84, 95% Cl: 0.81, 0.88) preserved the eye in three years. During follow-up, 91% (0.91, 95% Cl: 0.85, 0.97) patients survived and 351 of 1720 patients (0.23, 95% Cl: 0.09, 0.37) involving 1722 eyes had tumour recurrence. In addition, 1376 patients (0.79, 95% Cl: 0.77, 0.82) preserved the eyeball in five years. Following treatment, approximately 20% of patients had radiation retinopathy (95% Cl: 0.13, 0.28), 19% developed glaucoma (95% Cl: 0.11, 0.28), and 22% experienced retinal detachment (95% Cl: 0.07, 0.36).
Conclusions:
CKRT is a viable, noninvasive RT for UM. The rate of local tumour control following treatment is comparable to that of other RT approaches, providing additional options based on the patient’s condition.
What is Uveal Melanoma:
Uveal melanoma, also known as ocular melanoma, is a rare and potentially deadly cancer that occurs when melanocyte cells in the eye mutate and divide uncontrollably: Uveal melanoma is a cancer that starts in the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid.
How it occurs:
Uveal melanoma develops from a mutated melanocyte, a cell that produces melanin, the pigment that gives skin and eyes their color.
Symptoms:
Symptoms include blurred vision, a dark spot on the iris, floaters, or a change in the shape of the pupil.
Risk factors:
The risk of uveal melanoma increases with age and fair skin.
Treatment:
Early detection and treatment can improve the chances of a successful outcome.
Prognosis:
Uveal melanoma can spread quickly and resist treatment. The most common site of metastasis is the liver, but it can also spread to the lungs, bones, and skin. There is no cure for metastatic uveal melanoma.
Uveal melanoma is the most common type of eye cancer in adults, accounting for about 5% of all melanoma cases. In the United States, about 5,000 cases are diagnosed each year.
Here’s the link to the study:
https://www.nature.com/articles/s41433-024-03582-4?utm_source=dlvr.it&utm_medium=facebook
If you are diagnosed with an eye tumor, or eye cancer contact the cancer experts at CyberKnife Miami at 305-279-2900. They can guide you, helping you decide the best treatment option for your particular needs, whether that is CyberKnife or not.